ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 534

Effect of Baseline MTX Dose on Clinical Efficacy and Safety in Rheumatoid Arthritis Patients Treated with Filgotinib: Post-Hoc Analysis from a Phase 2B Study

René Westhovens1, Annegret Van der Aa2, Corinne Jamoul2, Chantal Tasset2 and Pille Harrison2, 1KU Leuven Department of Development and Regeneration, Skeletal Biology and Engineering Research Center, Leuven, Belgium, 2Galapagos NV, Mechelen, Belgium

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Janus kinase (JAK), methotrexate (MTX) and rheumatoid arthritis (RA)

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 5, 2017

Title: Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy Poster I: Comorbidities and Adverse Events; Efficacy and Safety of Small Molecules

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose:

Filgotinib (GLPG0634, GS-6034) is an oral, selective JAK1 inhibitor that has demonstrated safety and efficacy data in two 24-week placebo-controlled phase 2B studies as add-on to methotrexate and as monotherapy in active rheumatoid arthritis (RA) patients with inadequate response to MTX (MTX-IR)1,2.The objective was to assess the effect of MTX dose on clinical efficacy and safety in MTX-IR RA patients treated with filgotinib as add-on to background MTX for 24 weeks.

 

Methods:

Patients with active RA on stable dose of MTX were randomized in a double-blinded manner to receive either placebo (PBO) or one of 3 daily doses of filgotinib (50mg, 100mg or 200mg) as once or twice daily regimen for 24 weeks1. This post-hoc analysis includes patients treated with the selected Phase 3 filgotinib doses, 100mg and 200mg QD, and PBO for the efficacy parameters, and all dose groups for the safety analysis. MTX dose was categorized as low (≤12.5mg/wk), medium (>12.5 to <17.5 mg/wk) or high (≥17.5mg/wk).

 

Results:

Baseline disease activity was high and similar across the three MTX subgroups, with an overall mean DAS28(CRP) score of 6.10, mean HAQ-DI of 1.73, mean CDAI score of 42.10 and  mean SDAI score of 44.57. Across all MTX subgroups, patients on filgotinib 100mg or 200mg QD for 24 weeks showed efficacy over PBO, as measured by change from baseline in DAS28(CRP), CDAI, SDAI, HAQ-DI, and ACR20 response. No pattern was observed to suggest that the baseline MTX dose had any effect on filgotinib efficacy. The incidences of TEAE and serious TEAE were comparable regardless of the MTX dose (Table 2). 

 

Conclusion:

Post-hoc analysis of a phase 2B study in MTX-IR RA patients suggests that filgotinib treatment at 100mg and 200mg QD on the background of MTX is consistently associated with improved clinical outcomes compared to placebo, across all key efficacy parameters, irrespective of MTX dose. The safety profile was overall favorable and consistent with previous studies in RA with filgotinib, regardless of MTX dose.

Table 1. Mean (SE) change from baseline in key efficacy parameters at Week 24 by MTX subgroup.

 

 

 

PBO

filgotinib 100mg QD

filgotinib 200mg QD

 

Low MTX dose (≤12.5mg/wk)

 

N

14

9

8

DAS28(CRP)

-0.94 (0.28)

-1.96 (0.47)

-2.49 (0.43)

CDAI

-15.74 (4.67)

-23.32 (6.36)

-27.31 (5.27)

SDAI

-15.31 (4.68)

-24.87 (6.34)

-29.63 (5.70)

HAQ-DI

-0.30 (0.14)

-0.61 (0.26)

-0.73 (0.26)

 

Medium MTX dose (>12.5 to <17.5mg/wk)

 

N

43

48

44

 

DAS28(CRP)

-1.05 (0.23)

-2.77 (0.20)

-2.73 (0.21)

 

CDAI

-14.49 (2.81)

-29.73 (2.14)

-30.05 (2.04)

 

SDAI

-14.35 (2.92)

-31.49 (2.19)

-31.30 (2.23)

 

HAQ-DI

-0.36 (0.11)

-0.71 (0.09)

-0.79 (0.08)

 

High MTX dose (≥17.5mg/wk)

 

N

28

27

34

 

DAS28(CRP)

-1.51 (0.32)

-2.82 (0.30)

-2.97 (0.21)

 

CDAI

-18.67 (3.50)

-28.47 (2.76)

-29.18 (2.50)

 

SDAI

-18.36 (3.53)

-29.48 (2.86)

-30.95 (2.67)

 

HAQ-DI

-0.39 (0.10)

-0.94 (0.15)

-0.87 (0.13)

 

ACR20 by subgroup, n (%)

 

Low MTX dose (≤12.5mg/wk)

5 (36%)

4 (44%)

7 (88%)

 

Medium MTX dose (>12.5 to <17.5mg/wk)

18 (42%)

31 (65%)

32 (73%)

 

High MTX dose (≥17.5mg/wk)

13 (46%)

17 (63%)

24 (71%)

Table 2. Treatment-emergent adverse events (TEAE) and serious TEAEs at Week 24 by MTX subgroup.

 

% of patients

PBO

 

Filgotinib

 

Low MTX dose (≤12.5mg/wk)

TEAE

57

55

Serious TEAE

7

3

Medium MTX dose (>12.5 to <17.5mg/wk)

TEAE

47

46

Serious TEAE

2

2

High MTX dose (≥17.5mg/wk)

TEAE

57

57

Serious TEAE

7

2

References

1Westhovens R, et al. Ann Rheum Dis 2017;76:998-1008; 2Kavanaugh A, et al.Ann Rheum Dis 2017;76:1009-1019.

 


Disclosure: R. Westhovens, Bristol-Myers Squibb, 2,Roche Pharmaceuticals, 2,CellTrion, 5,Galapagos NV, 5; A. Van der Aa, Galapagos NV, 1,Galapagos NV, 3; C. Jamoul, Galapagos NV, 3; C. Tasset, Galapagos NV, 1,Galapagos NV, 3; P. Harrison, Galapagos NV, 1,Galapagos NV, 3.

To cite this abstract in AMA style:

Westhovens R, Van der Aa A, Jamoul C, Tasset C, Harrison P. Effect of Baseline MTX Dose on Clinical Efficacy and Safety in Rheumatoid Arthritis Patients Treated with Filgotinib: Post-Hoc Analysis from a Phase 2B Study [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/effect-of-baseline-mtx-dose-on-clinical-efficacy-and-safety-in-rheumatoid-arthritis-patients-treated-with-filgotinib-post-hoc-analysis-from-a-phase-2b-study/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/effect-of-baseline-mtx-dose-on-clinical-efficacy-and-safety-in-rheumatoid-arthritis-patients-treated-with-filgotinib-post-hoc-analysis-from-a-phase-2b-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology